Why Cancer Cells Are Addicted to Fuel: Understanding Metabolic Dependency, Growth Signalling, and Influence Over Prognosis
For much of modern medical history, cancer has been framed as a genetic accident — a random mutation, a fault in the DNA, a biological betrayal. And while mutations are unquestionably involved, that explanation alone has never been sufficient. A mutation may alter a cell’s potential, but potential does not build a tumour. Growth does.
Growth requires energy. Growth requires building materials. Growth requires biochemical instructions that say, repeatedly and persistently, “expand.”
If we are going to speak honestly about influence — not fantasy, not guarantees, but influence — then we must understand what growth depends on. And growth, at its most fundamental level, is metabolic.
In Australia, approximately 1 in 2 people will be diagnosed with cancer by the age of 85. In 2023 alone, more than 160,000 new cancer diagnoses were estimated nationally, with cancer remaining one of the leading causes of death across the country. Five-year relative survival across all cancers combined is now approximately 70%, a remarkable improvement compared to the 1980s, when it was closer to 50%. Yet those statistics mask enormous variation between tumour types. Survival outcomes for melanoma and prostate cancer are now high, while pancreatic, lung, and certain advanced gastrointestinal cancers remain far more challenging. Recurrence remains a major issue across multiple tumour types, particularly breast, colorectal, and melanoma.
Statistics matter. But statistics are population averages. They are retrospective. They describe what has happened. They do not describe what must happen.
To understand how biology can be influenced, we need to return to an observation made nearly a century ago.
In the 1920s, a German biochemist named Otto Warburg studied tumour tissue under controlled laboratory conditions. He noticed that cancer cells consumed glucose at unusually high rates and converted much of it into lactate, even when oxygen was plentiful. Under normal physiology, lactate production is associated with low oxygen states — sprinting, hypoxia, emergency metabolism. Cancer cells were doing this regardless of oxygen availability. This became known as aerobic glycolysis, or what we now call the Warburg effect.
Warburg believed impaired respiration was the root cause of cancer. That conclusion did not hold universally. Many cancers retain functional mitochondria. But his observation — that cancer cells metabolise fuel differently — has endured. Nearly one hundred years later, PET scans rely on this principle. Tumours often “light up” because they take up glucose more aggressively than surrounding tissue.
Why would a cell favour a less efficient way of generating ATP? Because ATP alone is not the objective. Rapid proliferation requires raw materials. Glycolysis provides intermediates that feed directly into pathways responsible for synthesising nucleotides for DNA and RNA, lipids for new cell membranes, and reducing equivalents such as NADPH that buffer oxidative stress. Efficiency is sacrificed for speed. Flexibility is sacrificed for growth velocity.
This shift from maintenance to expansion is not accidental. It is adaptive.
Glucose, therefore, is not merely fuel in cancer biology. It is construction material. Through the pentose phosphate pathway, glucose contributes to nucleotide synthesis. Through glycolytic intermediates, it supports amino acid and lipid production. Through redox balancing systems, it allows rapidly dividing cells to survive the oxidative stress generated by their own growth.
None of this means sugar “causes” cancer in the simplistic way social media sometimes suggests. But it does mean that chronic hyperglycaemia and hyperinsulinaemia alter the signalling terrain within which tumours exist.
Insulin is often misunderstood as a blood sugar hormone alone. In reality, it is a potent growth signal. When glucose rises, insulin rises. Insulin activates intracellular pathways such as PI3K–AKT and mTOR — the mechanistic target of rapamycin — a central nutrient-sensing hub that integrates information about amino acids, energy status, and growth factors. When mTOR activity is elevated, protein synthesis increases, cell cycle progression accelerates, and apoptosis is inhibited.
Under healthy physiology, insulin pulses. It rises after meals and falls between them. In metabolically flexible individuals, this rhythm is preserved. However, modern lifestyle patterns — frequent refined carbohydrate intake, disrupted sleep, sedentary behaviour, chronic stress — can lead to more sustained elevations in insulin. Epidemiological data from Australia and internationally have consistently linked insulin resistance and type 2 diabetes with increased risk of several cancers, including colorectal, breast (post-menopausal), and pancreatic cancers.
This is not about blame. It is about signalling.
Cancer does not require insulin to exist, but growth programs thrive in growth-permissive environments. When abundance signals are constant, the cellular instruction to “build” is amplified.
As metabolic research progressed through the early 2000s, another fuel source came into focus: glutamine. The most abundant amino acid in circulation, glutamine serves as a nitrogen donor for nucleotide synthesis and replenishes intermediates in the tricarboxylic acid cycle. It also contributes to glutathione production, one of the cell’s primary antioxidant systems. In many tumour types, glutamine consumption increases significantly, particularly under metabolic stress. If glycolysis is pressured, tumours may lean more heavily on glutamine pathways to maintain survival.
This adaptability is important. Cancer metabolism is not a single-pathway phenomenon. It is networked, dynamic, and responsive.
Further metabolomic advances revealed additional amino acid dependencies. Serine and glycine feed one-carbon metabolism, supporting nucleotide production and methylation reactions. Cysteine contributes to antioxidant buffering through glutathione. Arginine and asparagine have shown context-specific vulnerabilities in certain tumour types, with therapeutic strategies targeting these pathways in specific malignancies such as acute lymphoblastic leukaemia.
Among these, methionine has repeatedly drawn attention.
In the 1970s, researchers observed that many cancer cell lines failed to proliferate when methionine was removed from their environment, even when precursors such as homocysteine were available. Normal cells often adapted more effectively. This phenomenon, known as methionine dependence, did not immediately reshape oncology. At the time, genetic models dominated research priorities.
With the rise of epigenetics, methionine’s importance became clearer. Methionine is required to produce S-adenosylmethionine (SAM), the universal methyl donor in cells. Methylation reactions influence gene expression, including oncogenes and tumour suppressor genes. Methionine availability therefore intersects with DNA synthesis, epigenetic regulation, redox balance, and cell cycle control. Preclinical models have demonstrated that methionine restriction can slow tumour growth and enhance sensitivity to chemotherapy and radiation in specific contexts. These findings are not universal and require careful application, but they are biologically coherent.
This brings us to a crucial distinction: healthy cells and cancer cells do not respond identically to metabolic stress.
Human physiology evolved under fluctuating conditions. Periods of fasting alternated with feeding. Energy expenditure alternated with rest. Healthy cells retain the capacity to shift fuel sources, reduce proliferation, and enter repair modes in response to scarcity. This metabolic flexibility is protective.
Cancer cells, by contrast, often prioritise continuous growth signalling. In committing so heavily to expansion, they may lose some adaptability. Research into fasting and fasting-mimicking strategies has explored the concept of differential stress tolerance — the idea that healthy cells can activate protective pathways under metabolic stress while tumour cells struggle to adapt. Early clinical and preclinical research has suggested that short-term, strategically timed metabolic modulation may enhance treatment sensitivity in certain settings.
None of this suggests starvation. It does not suggest extremism. Nutritional status is critical in cancer care, particularly in the context of cachexia and treatment-related weight loss. The objective is not chronic deprivation but strategic modulation.
Cancer statistics in Australia show both progress and limitation. Five-year survival has improved significantly over recent decades, yet recurrence remains common in several tumour types. For example, breast cancer five-year survival exceeds 90%, yet recurrence rates can range between 10–30% depending on subtype and stage. Colorectal cancer survival has improved to around 70% at five years, yet metastatic disease still carries substantial mortality. Melanoma outcomes have dramatically improved with immunotherapy, yet advanced cases still require aggressive management.
These realities demand both realism and agency.
Cancer is not purely genetic. It is not purely metabolic. It is not purely immunological. It is a dynamic interplay of mutation, signalling, metabolism, microenvironment, and host resilience.
Fuel availability influences signalling. Signalling influences cellular behaviour. Behaviour influences tumour dynamics.
No intervention guarantees an outcome. Biology is probabilistic, not deterministic. Yet influence exists. Insulin sensitivity can improve. Muscle mass can increase. Sleep patterns can stabilise. Stress physiology can be regulated. Metabolic flexibility can be trained.
Your body is not broken. It is responsive.
Cancer is driven by signals, not fate alone. And every input — nutritional, hormonal, behavioural, environmental — shapes the terrain those signals act upon.
Metabolic flexibility is not theory. It is physiology. And physiology, over time, responds to consistency.
Understanding what cancer depends on does not create certainty. But it does create leverage.
And leverage, applied intelligently, shifts probability.
.
.
References
Australian Institute of Health and Welfare (AIHW). Cancer in Australia 2023. Canberra: AIHW; 2023.
Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144(5):646–674.
Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016;41(3):211–218.
Pavlova NN, Thompson CB. The Emerging Hallmarks of Cancer Metabolism. Cell Metab. 2016;23(1):27–47.
Zhang J et al. Cancer Metabolic Reprogramming: Recent Advances and Therapeutic Strategies. Cancers (Basel). 2022;14(19):4568.
Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016;16(10):619–634.
Hoffman RM. Altered methionine metabolism and transmethylation in cancer. Anticancer Res. 1985;5(1):1–30.
Longo VD, Mattson MP. Fasting: Molecular Mechanisms and Clinical Applications. Cell Metab. 2014;19(2):181–192.
Giovannucci E et al. Diabetes and Cancer: A Consensus Report. CA Cancer J Clin. 2010;60(4):207–221.